[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"egg-allergy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:egg-allergy":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,43,86,110,138,169],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100535770","investigating-modified-protocols-of-oral-immunotherapy-to-validate-efficacy-and-safety-100535770",false,"NCT06256146","Investigating Modified Protocols of Oral Immunotherapy to Validate Efficacy and Safety","IMPROVES","Inclusion Criteria:\n\n* A history suggestive of immediate allergy to the food. A convincing clinical history of an IgE mediated reaction to a specific food will be defined as a minimum of 2 mild signs\u002Fsymptoms or 1 moderate or 1 severe sign\u002Fsymptom that was likely IgE mediated and occurred within 120 minutes after ingestion or contact\n* The presence of at least one of the following confirmatory tests:\n\n  * Positive SPT to the culprit food allergen (weal diameter 3 mm larger than that of the normal saline control). The allergens used will be commercial extracts of the foods (Omega Labs, Toronto, Ontario).\n  * Detection of serum specific IgE (\\>0.35 kU\u002FL) to the culprit food or any of its proteins, measured by fluorescence enzyme immunoassay (Phadia, CAP System, Uppsala, Sweden).\n\nExclusion Criteria:\n\n* Patients who have uncontrolled respiratory disease (asthma, cystic fibrosis, etc.)\n* Patients who present with intercurrent disease active at the time of starting desensitization.\n* Non IgE mediated or non-immunological adverse reactions to milk or peanuts.\n* Malignant or immunopathological diseases and\u002For severe primary or secondary immune deficiencies.\n* Patients receiving oral immunosuppressor therapy.\n* Patients receiving β-blockers (including topical formulations), or who receive daily doses of NSAIDs, aspirin or ACE inhibitors for cardiac issues.\n* Associated diseases contraindicating the use of epinephrine: cardiovascular disease, severe hypertension or hypotension.\n* Patients diagnosed with eosinophilic gastrointestinal disorders, including patients with a history of antacid use for reflux related to food impaction or with a history of esophageal spasm.\n* Patients already tolerating processed\u002Fcooked forms of the food (e.g.,baked goods with milk).","ALL","2 Years","40 Years",{"count":20,"type":21},360,"ESTIMATED","INTERVENTIONAL",[24],"NA","Protocols for Oral Immunotherapy (OIT) for the main food allergens have been recently incorporated in clinical practice for food allergies and their clinical benefits have been acknowledged in European and Canadian official guidelines. There has been some reluctance in both clinicians and patients to implement these therapies, primarily because of the risk of allergic reactions during the desensitization process. This study will investigate if protocols using low doses of a food allergen or processed versions of the allergen can be both effective in conferring desensitization while inducing fewer allergic symptoms during the desensitization process.",[27,28,29],"Peanut Allergy","Milk Allergy, Cow's","Egg Allergy","RECRUITING","2026-05-01",{"date":33,"type":34},"2026-05-07","ACTUAL",{"date":36,"type":34},"2022-03-01",{"date":38,"type":21},"2030-02-28",{"name":40,"class":41},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":42},"100591157","phase-2-comparison-between-a-rush-and-a-conventional-oral-immunotherapy-protocol-to-treat-cows-milk-and-hens-egg-allergy-compito-study-100591157","NCT06976775","Comparison Between a Rush and a Conventional Oral Immunotherapy Protocol to Treat Cow's Milk and Hen´s Egg Allergy. CompITO Study","Comparative Analysis Between Two Oral Immunotherapy Schemes in Cow´s Milk and\u002For Hen´s Egg Allergic Children to Improve Treatment Efficiency and Identify Response Biomarkers. CompITO Study","compITO","Inclusion Criteria:\n\n* Patients 6 to 16 years old\n* sIgE levels to milk 0.35 to 35kUA\u002FL for milk allergic subjects and egg 0.35 to 35kUA\u002FL for egg allergic subjects\n* Entry DBPCFC discrete milk eliciting dose (ED)≥ 22.2mg of milk protein and discrete egg ED≥18.5mg of egg protein, that are the population-based reference values for the ED20\n* Having a mild to moderate food allergy severity per DEFASE score (\\\u003C13 points)\n\nExclusion Criteria:\n\n* sIgE levels to milk \\>35kUA\u002FL for milk allergic subjects and egg \\> 35kUA\u002FL for milk allergic subjects\n* Entry DBPCFC discrete milk ED\\\u003C22.2mg of milk protein or discrete egg ED\\\u003C18.5mg of egg protein\n* Entry DBPCFC discrete ED for milk\\>2112mg of milk protein (cumulative amount of 4193,7mg of milk protein) and egg discrete ED\\>1560mg of egg protein (cumulative amount of 3110.8mg of egg protein)\n* Having severe food allergy per DEFASE score (≥13 points)\n* Other exclusion criteria: uncontrolled asthma, FEV1\\\u003C70%, severe atopic dermatitis, Eosinophilic Esophagitis, non-IgE mediated allergy, having started SCIT 3 months before, or SLIT one week before. Pregnancy","6 Years","16 Years",{"count":54,"type":21},40,[56,57],"PHASE2","PHASE3","This study investigates the efficacy and safety of two different OIT schemes to treat milk and egg allergic children",[60,61,29],"Food Allergy in Children","Milk Allergy",[63,64,65,66,67,68,69,70,71,72,73,74,75,76],"Food immunotherapy","Allergy","Milk","Egg","Oral immunotherapy","Anaphylaxis","Mast cell activation test","Saliva","Blood","IgE","Food allergy","Sensitization","Children","Pediatric","2026-02-16",{"date":79,"type":34},"2026-02-18",{"date":81,"type":34},"2025-06-03",{"date":83,"type":21},"2027-04-30",{"name":85,"class":41},"Pablo Rodríguez del Rio",{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":96,"phases":4,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":42},"100620558","a-long-term-observational-follow-up-study-of-children-and-young-people-who-underwent-an-18-month-course-of-oral-immunotherapy-treatment-for-peanut-egg-or-milk-allergy-5-15-years-post-treatment-100620558","NCT07359183","A Long Term, Observational Follow-Up Study of Children and Young People Who Underwent an 18-Month Course of Oral Immunotherapy Treatment for Peanut, Egg or Milk Allergy (5-15 Years Post-Treatment)","Long Term Outcomes Associated With Attainment of Remission Following Oral Immunotherapy to Peanut, Egg and Cow's Milk (LPEM Study)","LPEM","Inclusion Criteria:\n\n* Previous participant of PEAT, PrEMO, PPOIT-001 or PPOIT-002 parent study\n* Received at least one dose of OIT treatment in the parent study\n* Written informed consent from participant and\u002For parent\u002Fguardian (if below 18 years of age)\n\nExclusion Criteria:\n\n-Have any conditions that, in the opinion of the investigator, precludes participation for reason of safety",{"count":95,"type":21},147,"OBSERVATIONAL","The goal of this observational study is to learn about the long-term outcomes of children and young people who underwent an 18-month course of oral immunotherapy (OIT) treatment for peanut, egg or milk allergy. It aims to:\n\n• Compare long-term changes in health-related quality of life (HRQL) at 5-15 years after stopping OIT in participants who achieved remission and those who did not.\n\nParticipants will attend a single follow-up visit for:\n\n* A blood test\n* Skin prick test (SPT)\n* Allergy questionnaires",[99,100,29,61],"Food Allergies","Peanut Allergies","2026-01-29",{"date":103,"type":34},"2026-02-02",{"date":105,"type":34},"2026-01-13",{"date":107,"type":21},"2027-01",{"name":109,"class":41},"Murdoch Childrens Research Institute",{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":117,"sex":118,"minAge":119,"maxAge":18,"enrollmentInfo":120,"targetDuration":4,"studyType":22,"phases":122,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":42},"100536140","expecting-mothers-study-of-consumption-or-avoidance-of-peanut-and-egg-100536140","NCT06260956","Expecting Mother's Study of Consumption or Avoidance of Peanut and Egg","ESCAPE","Inclusion Criteria:\n\n• o Subject must be able to understand and provide informed consent.\n\n* English-speaking adults, 18 years or older. (Spanish speaking adults may be included after consent document is translated and Spanish speaking study representatives are available to conduct and answer questions during informed consent process and for study follow up.)\n* Maternal consent must be provided for infants.\n* Pregnant women from the time pregnancy is confirmed until 27 weeks of gestation.\n* Self-reported at time of enrollment:\n\n  * no chronic inflammatory conditions that require long-term systemic immunosuppressive medications in first or second trimester\n  * carrying a fetus with a first-degree relative (i.e., mother, father, full sibling) with any self-reported or physician-diagnosed allergic disease (asthma, allergic rhinitis, atopic dermatitis, or food allergy).\n* Intend to give their infant their own breast milk for more than 3 months.\n* Can confidently say they have eaten PN and egg and have tolerated consumption with no food allergy reactions.\n* Willing to be randomized to consumption or avoidance diet.\n* Uncomplicated pregnancy (no gestational diabetes, no preeclampsia, no hyperemesis gravidarum), self-reported at time of enrollment.\n\nExclusion Criteria:\n\n* Inability or unwillingness of subject to give written informed consent or comply with study protocol.\n* Known history of renal\u002Fliver\u002Fcardiac insufficiency in the mother or infant.\n* Pregnant women with PN or egg allergy.\n* Pregnant women who refuse to eat PN (or peanut products) and\u002For eggs.\n* Physician diagnosed immunodeficiency in the mother or infant.\n* Current, diagnosed, mental illness or current, diagnosed, or self-reported, drug or alcohol abuse that, in the opinion of the investigator, would interfere with the subject's ability to comply with study requirements.\n* Past or current medical problems or findings from medical history that are not listed above, which, in the opinion of the investigator, may pose additional risks to the mother or infant from participation in the study, may interfere with the subject's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.",true,"FEMALE","18 Years",{"count":121,"type":21},500,[24],"Peanut allergy is the most common cause of fatal and near-fatal food-allergic reactions and egg allergy is among the two most common causes of food-induced anaphylaxis. The proposed research will explore the development of sensitization to these food(s) in infants based on maternal consumption or avoidance during pregnancy and breastfeeding.",[125,126,29,127,128],"Allergy and Immunology","Peanut and Nut Allergy","Food Allergy in Infants","Food Allergy Peanut","2025-08-08",{"date":131,"type":34},"2025-08-13",{"date":133,"type":34},"2025-08-01",{"date":135,"type":21},"2029-09",{"name":137,"class":41},"University of Rochester",{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":16,"minAge":145,"maxAge":146,"enrollmentInfo":147,"targetDuration":4,"studyType":22,"phases":149,"briefSummary":150,"conditions":151,"keywords":154,"overallStatus":158,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":168},"100596027","efficacy-and-safety-of-egg-ladders-in-children-with-ige-mediated-hens-egg-protein-allergy-100596027","NCT07040111","Efficacy and Safety of Egg Ladders in Children With IgE-Mediated Hen's Egg Protein Allergy","Efficacy and Safety of a 4-Step Versus a 5-Step Egg Ladder in Children With IgE-Mediated Hen's Egg Protein Allergy: Protocol for an Open-Label Randomized Controlled Trial","Inclusion Criteria:\n\n* Age ≥ 12 months and ≤ 5 years.\n* Diagnosis of IgE-mediated HEA confirmed according to the EAACI guidelines by a positive OFC with hen's egg proteins. In children with high-risk HEA (e.g., history of anaphylaxis), diagnosis can be based on elevated specific IgE levels (3.5 kU\u002Fl) to hen's egg proteins and\u002For individual egg components and\u002For positive skin tests.\n* On a therapeutic elimination diet for at least 6 months, measured from the last allergic reaction to egg (in accordance with BSACI guidelines).\n* Eligible regardless of the risk of systemic reactions (e.g. anaphylaxis) or asthma.\n* Good general health.\n* Written informed consent signed by the child's guardians.\n* Demonstrated good cooperation from the patient's guardians.\n\nExclusion Criteria:\n\n* Confirmed wheat allergy and\u002For celiac disease.\n* Uncontrolled asthma, defined as the presence of shortness of breath, cough, chest tightness, or auscultatory changes despite treatment.\n* Signs of exacerbation of a chronic disease.\n* Signs of acute infectious disease (e.g. acute rhinitis, cough, subfebrile or febrile states).\n* Signs of exacerbation of another allergic disease (e.g., conjunctivitis, allergic rhinitis, atopic dermatitis).\n* Anaphylaxis due to hen's egg proteins within the last 6 months.\n* Use of antihistamines within 3-10 days before the challenge (depending on the drug and indication; time-limited contradiction - relative exclusion criterion).\n* Acquired tolerance to baked hen's egg proteins or advancement to a higher step of the egg ladder.\n* Use of immunosuppressive drugs or immunotherapy.","1 Year","5 Years",{"count":148,"type":21},94,[24],"Hen's Egg Allergy is one of the most common food allergies in early childhood. The first-line treatment is the elimination of hen's egg proteins from the child's or maternal diet.\n\nAvailable data from the literature indicate that most children with hen's egg allergy acquire tolerance to hen's egg proteins with age. An assessment of tolerance acquisition to them is commonly performed using egg ladder. However, scientific evidence regarding the effectiveness and safety of the egg ladder in children with hen's egg allergy is limited. Currently, there is no standardised egg ladder protocol, and different versions of the ladder and recommend by scientific societies in various countries.\n\nThis study aims to assess the effectiveness and safety of the 4-step egg ladder (4-EL) compared to the 5-step egg ladder (5-EL) in children with IgE-mediated hen's egg allergy. This is an open-label, randomised superiority trial with two parallel arms and a 1:1 allocation ratio.",[152,29,153],"Food Allergy","Hen Egg Allergy",[155,156,157],"children","egg ladder","IgE-mediated hen egg allergy","NOT_YET_RECRUITING","2025-06-26",{"date":161,"type":34},"2025-07-01",{"date":163,"type":21},"2025-07",{"date":165,"type":21},"2028-11",{"name":167,"class":41},"Medical University of Warsaw",2,{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":52,"enrollmentInfo":175,"targetDuration":4,"studyType":22,"phases":177,"briefSummary":178,"conditions":179,"keywords":180,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":168},"100496126","oral-immunotherapy-for-egg-allergy-in-children-aged-6-to-16-100496126","NCT05740163","Oral Immunotherapy for Egg Allergy in Children Aged 6 to 16","Inclusion Criteria:\n\n* Age 6 to 16 years\n* Elevated spesific serum IgE to egg (\\> 5 kU\u002Fl) and\u002For positive skin prick to egg allergen\n* Positive oral food challenge for egg or anaphylaxis reaction to egg within the 6 months\n* Diet free from egg in any form\n\nExclusion Criteria:\n\n* Age less than 6 years or more than 16 years\n* Poor asthma control or uncontrolled asthma\n* Severe\u002Fsignificant cardiovascular disease\n* Autoimmune disease\n* Malignancy\n* Medication: beta bloker, angiotensin-converting-enzyme inhibitors (ACE inhibitors), Monoamine oxidase inhibitors (MAOIs)\n* Poor compliance\n* Fear of immunotherapy\n* Desensitization to alfa-gal-protein (mammalian meat allergy)",{"count":176,"type":21},60,[24],"The aim of the study is to determine the efficacy of a 12-month egg oral immunotherapy (OIT) protocol with a cooked whole egg product including yolk and egg white.\n\nStudy hypothesis: With this method the risk for severe allergic reaction to egg protein is reduced and the diet can partly or completely be normalized.",[29],[67,181,75],"Egg allergy","2024-04-09",{"date":184,"type":34},"2024-04-10",{"date":186,"type":34},"2019-12-30",{"date":188,"type":21},"2026-12-31",{"name":190,"class":41},"Tampere University Hospital"]